We bring execution discipline to the operational backbone of pharmaceutical commercial teams. We do not diagnose to report. We diagnose to operationalize.
Select a stage to see the service lines within it. Every capability sits on this spine.
What does the landscape look like, and where do the commercial constraints lie?
How big is the opportunity, how reachable is it, and what is the access pathway?
How do we deploy the field force, incentivize the team, and set the plan?
How is performance tracking daily, and where do we optimize the system?
Every engagement is grounded in therapy-area reality, across the US, EU, UK, GCC, and India.
Solid tumours and hematologic malignancies — NSCLC, breast, prostate, colorectal, multiple myeloma, lymphoma, and CLL: line-of-therapy architecture, biomarker-defined segments, and the payer dynamics that govern access.
Orphan and ultra-rare conditions — SMA, Duchenne, cystic fibrosis, hemophilia, and lysosomal storage disorders: patient identification, the diagnostic odyssey, and access patterns unique to small, dispersed populations.
Neurology and neuropsychiatry — Alzheimer's, Parkinson's, multiple sclerosis, migraine, schizophrenia, and depression: where diagnosis rates and adherence shape the commercial model.
Originator defence and biosimilar entry — adalimumab, trastuzumab, rituximab, and insulin biosimilars: switching dynamics, tender strategy, and erosion modelling across regulated markets.
We work across regulated and emerging markets, grounded in each one's reimbursement and access machinery.
AMNOG and G-BA benefit assessment, GKV reimbursement, AMNOG price negotiation, and Festbetrag reference pricing.
HAS Transparency Committee assessment, ASMR and SMR rating, and CEPS price negotiation.
NICE and SMC health technology assessment, NHS access frameworks, and managed access agreements.
SFDA and UAE regulatory pathways, NUPCO tendering, and reference-country pricing across KSA, UAE, Qatar, Kuwait, Oman, and Bahrain.
Global Capability Center operating models, emerging-market access, and patient-funnel modelling for India launches.
Payer and PBM access, Inflation Reduction Act implications, and commercial launch strategy.
Bring a live commercial question: your therapeutic area, market, and scope. AXLRx returns a consulting-grade, fully sourced brief in days. Your first one is complimentary, a $2,000 value.
Tell us about your challenges and we will design the right engagement.